Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Raw Materials (2020 - 2025)

IceCure Medical has reported Raw Materials over the past 6 years, most recently at $1.8 million for Q4 2025.

  • For Q4 2025, Raw Materials rose 28.2% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $1.8 million, up 28.2%, while the annual FY2025 figure was $1.8 million, 28.2% up from the prior year.
  • Raw Materials was $1.8 million for Q4 2025 at IceCure Medical, up from $1.4 million in the prior quarter.
  • Across five years, Raw Materials topped out at $1.8 million in Q4 2025 and bottomed at $704000.0 in Q4 2021.
  • The 5-year median for Raw Materials is $1.4 million (2024), against an average of $1.4 million.
  • Year-over-year, Raw Materials surged 122.44% in 2022 and then dropped 11.17% in 2023.
  • Over 5 years, Raw Materials stood at $704000.0 in 2021, then skyrocketed by 122.44% to $1.6 million in 2022, then dropped by 11.17% to $1.4 million in 2023, then grew by 1.22% to $1.4 million in 2024, then rose by 28.2% to $1.8 million in 2025.
  • The last three reported values for Raw Materials were $1.8 million (Q4 2025), $1.4 million (Q4 2024), and $1.4 million (Q4 2023) per Business Quant data.